[1]
S. Kader, K. J.Al-Shamma, I. A. Majeed, and A. T. Al-Ani, “Comparative Study between Oral Hypoglycemic Drugs Repaglinide, Glibenclamide and Rosiglitazone on Some Biochemical Parameters in Type 2 Diabetic Patients”, Iraqi Journal of Pharmaceutical Sciences , vol. 18, no. 2, pp. 32–38, Mar. 2017, doi: 10.31351/vol18iss2pp32-38.